SCHEMBL5373022

SCHEMBL5373022

CC(C)(C)ON(C=O)NCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.42
ADH1C P00326 1/20 0.42
ADH1A P07327 1/20 0.42
ADH7 P40394 1/20 0.42
CA12 O43570 2/20 0.38
CA7 P43166 2/20 0.38
CA14 Q9ULX7 2/20 0.38
CA1 P00915 1/20 0.38
ATM Q13315 1/20 0.38
RIPK1 Q13546 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
KDM4E B2RXH2 2/20 0.36
CYP3A4 P08684 1/20 0.36
MAPT P10636 1/20 0.36
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
HSD17B10 Q99714 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7061205 0.84 RAB9A (0.40) KDM4ELMNARAB9ASMN1; SMN2GAA
SCHEMBL5767016 0.83 MMP8 (0.39) CA12CA1KMT2AMEN1TDP1
SCHEMBL7064438 0.83 CYP1A2 (0.49) KMT2AMEN1TDP1KDM4ECYP3A4
SCHEMBL7062337 0.79 FAAH (0.33) KMT2AMEN1TDP1MAPT
SCHEMBL7061210 0.78 SMN1; SMN2 (0.42) KMT2AMEN1KDM4ERAB9AHSD17B10
SCHEMBL5767231 0.77 CHRM2 (0.44) KMT2AMEN1TDP1KDM4EMAPT
SCHEMBL7059655 0.76 TSHR (0.41) ATMKMT2AMEN1TDP1KDM4E
SCHEMBL5767277 0.76 ESR1 (0.41) CA1CA2
SCHEMBL27968389 0.72 EPHX2 (0.43)
SCHEMBL6762362 0.72 RIPK1 (0.37) RIPK1KMT2AMEN1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253169-B2 Aza compounds, pharmaceutical compositions and methods of use GLIAMED, INC. (US) 2007-08-07 US disclosed
EP-1242383-A1 AZA COMPOUNDS HAVING NEURONAL ACTIVITY GPI NIL Holdings, Inc. (US) 2002-09-25 EP disclosed
US-6417189-B1 DRUGS WITH PYRAZOLE KETONE DERIVATIVES GPI NIL HOLDINGS, INC. 2002-07-09 US disclosed
US-20020028814-A1 Aza compounds, pharmaceutical compositions and methods of use GLIAMED, INC. 2002-03-07 US disclosed
WO-2001079177-A1 CYCLIC DIAZA COMPOUNDS FOR TREATING NEURODEGENERATIVE DISORDERS GPI NIL HOLDINGS, INC. (US) 2001-10-25 WO disclosed
WO-2001036388-A1 AZA COMPOUNDS HAVING NEURONAL ACTIVITY GPI NIL HOLDINGS, INC. (US) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028814-A1 Aza compounds, pharmaceutical compositions and methods of use GRIN3A, CHRNA5, GRIN3B ADH1B 818/4885ADH1C 1352/4885ADH1A 1375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.